Clinical Trial Update: Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis [Phase 2]

View source ↗

Summary

Phase 2 study of etrasimod for immune checkpoint inhibitor-related diarrhea and colitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Checkpoint Inhibitor-related Diarrhea and Colitis

Drugs mentioned

• Etrasimod (etrasimod)

Snippet

Sponsor: Yale University | Conditions: Immune Checkpoint Inhibitor-Related Diarrhea and Colitis | Phase 2 | Status: WITHDRAWN